Kodiak Sciences Inc. (NYSE:KOD) rose 1.2% during trading on Monday . The company traded as high as $22.25 and last traded at $21.68, approximately 5,454 shares changed hands during mid-day trading. A decline of 96% from the average daily volume of 150,187 shares. The stock had previously closed at $21.42.
KOD has been the topic of a number of recent research reports. Chardan Capital increased their target price on Kodiak Sciences from $22.50 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, October 15th. Zacks Investment Research raised Kodiak Sciences from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research note on Saturday. Five research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $22.40.
The firm has a 50-day moving average of $16.20 and a 200 day moving average of $11.97.
Kodiak Sciences (NYSE:KOD) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.02).
Several institutional investors have recently added to or reduced their stakes in KOD. JPMorgan Chase & Co. boosted its position in shares of Kodiak Sciences by 179.7% during the second quarter. JPMorgan Chase & Co. now owns 6,476 shares of the company’s stock valued at $73,000 after buying an additional 4,161 shares during the last quarter. Marshall Wace North America L.P. purchased a new stake in shares of Kodiak Sciences during the first quarter valued at $73,000. Hillsdale Investment Management Inc. purchased a new stake in shares of Kodiak Sciences during the second quarter valued at $99,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Kodiak Sciences during the second quarter valued at $122,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Kodiak Sciences during the second quarter valued at $164,000.
About Kodiak Sciences (NYSE:KOD)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.
Featured Article: Understanding each part of a balance sheet
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.